Abstract
Franciscan missionary Giovanni Di Plano Carpini traveled in 1245 to a country named Yeke Tartar, to visit a certain man called Genghis Khan. His journeys report narrated peculiar dietary habits of the locals: “they eat anything, even lice”. Little that Carpini knew, he had actually documented the earliest known to us record of oral vaccination against blood-borne infections – an approach that is still used occasionally in the present-day Mongolia for therapy of hepatitis. Currently, efforts aimed at developing therapeutic hepatitis vaccines have switched to more palatable path, but we may still benefit from the insight of medieval Mongols. This review provides an update on development of hepatitis B and C vaccines as related to immunotherapy of hepatitis. Immune therapy is a fast-moving field but the results so far failed to pitch woo. Current trends in research on therapeutic vaccine candidates and liver immunology are discussed. We subscribe to the idea that viral hepatitis is essentially an autoimmune disease generating immune-mediated liver damage. Therapeutic vaccines need to be designed in such a way that self-destructive immunity of the host is targeted not the virus, which is not cytopathic.
Keywords: Therapeutic Vaccines, Hepatitis, lice, oral vaccination, immunotherapy
Current Pharmaceutical Design
Title: Clinical Experience with Therapeutic Vaccines Designed for Patients with Hepatitis
Volume: 15 Issue: 11
Author(s): Dendev Batdelger, Dorjiin Dandii, Yagaanbuyant Dahgwahdorj, Erdene Erdenetsogt, Janchivyn Oyunbileg, Navaansodov Tsend, Bold Bayarmagnai, Vichai Jirathitikal and Aldar S. Bourinbaiar
Affiliation:
Keywords: Therapeutic Vaccines, Hepatitis, lice, oral vaccination, immunotherapy
Abstract: Franciscan missionary Giovanni Di Plano Carpini traveled in 1245 to a country named Yeke Tartar, to visit a certain man called Genghis Khan. His journeys report narrated peculiar dietary habits of the locals: “they eat anything, even lice”. Little that Carpini knew, he had actually documented the earliest known to us record of oral vaccination against blood-borne infections – an approach that is still used occasionally in the present-day Mongolia for therapy of hepatitis. Currently, efforts aimed at developing therapeutic hepatitis vaccines have switched to more palatable path, but we may still benefit from the insight of medieval Mongols. This review provides an update on development of hepatitis B and C vaccines as related to immunotherapy of hepatitis. Immune therapy is a fast-moving field but the results so far failed to pitch woo. Current trends in research on therapeutic vaccine candidates and liver immunology are discussed. We subscribe to the idea that viral hepatitis is essentially an autoimmune disease generating immune-mediated liver damage. Therapeutic vaccines need to be designed in such a way that self-destructive immunity of the host is targeted not the virus, which is not cytopathic.
Export Options
About this article
Cite this article as:
Batdelger Dendev, Dandii Dorjiin, Dahgwahdorj Yagaanbuyant, Erdenetsogt Erdene, Oyunbileg Janchivyn, Tsend Navaansodov, Bayarmagnai Bold, Jirathitikal Vichai and Bourinbaiar S. Aldar, Clinical Experience with Therapeutic Vaccines Designed for Patients with Hepatitis, Current Pharmaceutical Design 2009; 15 (11) . https://dx.doi.org/10.2174/138161209787846793
DOI https://dx.doi.org/10.2174/138161209787846793 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Local Treatment for Lymphoid Malignancies of the Eye
Anti-Cancer Agents in Medicinal Chemistry Statins, Mevalonate Pathway and its Intermediate Products in Placental Development and Preeclampsia
Current Molecular Pharmacology Role of Mu and Delta Opioid Receptors in Alcohol Drinking Behaviour
Current Drug Abuse Reviews Recent Advances in Optical Cancer Imaging of EGF Receptors
Current Medicinal Chemistry Pentacyclic Triterpenoids and Their Saponins with Apoptosis-Inducing Activity
Current Topics in Medicinal Chemistry Glutamate Transporter 1: Target for the Treatment of Alcohol Dependence
Current Medicinal Chemistry Bortezomib in the Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Insulin-Like Growth Factor 2 - The Oncogene and its Accomplices
Current Pharmaceutical Design Targeting Nodal and Cripto-1: Perspectives Inside Dual Potential Theranostic Cancer Biomarkers
Current Medicinal Chemistry NSAIDs and Chemoprevention
Current Cancer Drug Targets The Therapeutic Potential of Adenosine Triphosphate as an Immune Modulator in the Treatment of HIV/AIDS: A Combination Approach with HAART
Current HIV Research Extracellular Vesicles in Glioblastoma: Role in Biological Processes and in Therapeutic Applications
Current Cancer Drug Targets Cyclodextrins and their Derivatives as Carrier Molecules in Drug and Gene Delivery Systems
Current Organic Chemistry Glucose Transporters Regulation on Ischemic Brain: Possible Role as Therapeutic Target
Central Nervous System Agents in Medicinal Chemistry Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain
CNS & Neurological Disorders - Drug Targets PREFACE
Anti-Cancer Agents in Medicinal Chemistry Membrane Targeted Chemotherapy with Hybrid Liposomes for Tumor Cells Leading to Apoptosis
Current Pharmaceutical Design Targeting Tumor Microenvironment with Silibinin: Promise and Potential for a Translational Cancer Chemopreventive Strategy
Current Cancer Drug Targets Hypoxia-Inducible Factor: A Potential Therapeutic Target for Rheumatoid Arthritis
Current Drug Targets An Update on Circumventing Multidrug Resistance in Cancer by Targeting P-Glycoprotein
Current Cancer Drug Targets